JP2011515409A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011515409A5 JP2011515409A5 JP2011500916A JP2011500916A JP2011515409A5 JP 2011515409 A5 JP2011515409 A5 JP 2011515409A5 JP 2011500916 A JP2011500916 A JP 2011500916A JP 2011500916 A JP2011500916 A JP 2011500916A JP 2011515409 A5 JP2011515409 A5 JP 2011515409A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010030043 Ocular hypertension Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000003779 hair growth Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 0 C[C@@](CNC1(CCC1)N)[C@@]1[C@@](CCCc2ccc(*)[n]2)[C@@](*)C[C@]1* Chemical compound C[C@@](CNC1(CCC1)N)[C@@]1[C@@](CCCc2ccc(*)[n]2)[C@@](*)C[C@]1* 0.000 description 2
Claims (15)
- 下記の構造を有する化合物、またはその製薬上許容し得る塩:
(式中、Yは、下記:
であり;
Aは、‐(CH2)6‐、シス‐CH2CH=CH‐(CH2)3‐、または‐CH2C≡C‐(CH2)3‐であり、これらにおいて、1個または2個の炭素原子はSまたはOによって置換し得;或いは、Aは、‐(CH2)m‐Ar‐(CH2)o‐であり、式中、Arはインターアリーレンまたはヘテロインターアリーレンであり、mとoの和は1、2、3または4であり、1個のCH2はSまたはOによって置換し得;
R1は、CNまたはOHであり;
R2は、H、CN、OH、F、Cl、BrまたはCH3であるが、R1がOHである場合は、R2はOHでないことを条件とし;
Zは、CH2CHOH、CHOHCH2またはCHOHであり;
Gは、L、CH2L、OLまたはSLであり;
Lは、フェニル、単環式ヘテロアリールまたはC1‐6アルキルである)。 - 緑内障または高眼圧症の治療用組成物を製造するための、請求項1〜12のいずれか一項に記載の化合物の使用。
- 脱毛症の治療用組成物を製造するための、請求項1〜12のいずれか一項に記載の化合物の使用。
- 育毛の刺激用組成物を製造するための、請求項1〜12のいずれか一項に記載の化合物の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3762208P | 2008-03-18 | 2008-03-18 | |
US61/037,622 | 2008-03-18 | ||
US12/405,349 | 2009-03-17 | ||
US12/405,349 US7960378B2 (en) | 2008-03-18 | 2009-03-17 | Therapeutic compounds |
PCT/US2009/037477 WO2009117467A2 (en) | 2008-03-18 | 2009-03-18 | Therapeutic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011515409A JP2011515409A (ja) | 2011-05-19 |
JP2011515409A5 true JP2011515409A5 (ja) | 2012-05-17 |
Family
ID=41089556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011500916A Ceased JP2011515409A (ja) | 2008-03-18 | 2009-03-18 | 治療用化合物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7960378B2 (ja) |
EP (1) | EP2279169A2 (ja) |
JP (1) | JP2011515409A (ja) |
AU (1) | AU2009225693B2 (ja) |
BR (1) | BRPI0909764A2 (ja) |
CA (1) | CA2718713A1 (ja) |
WO (1) | WO2009117467A2 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2303836A1 (en) * | 2008-05-09 | 2011-04-06 | Allergan, Inc. | Therapeutic cyclopentane derivatives |
US8299068B2 (en) * | 2010-01-29 | 2012-10-30 | Allergan, Inc. | Therapeutically active cyclopentanes |
WO2015175075A1 (en) * | 2014-02-20 | 2015-11-19 | Allergan, Inc. | Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes |
CN111018826B (zh) * | 2019-12-25 | 2020-11-10 | 西华大学 | 2-氰基-5-氧代戊酸乙酯类化合物及其应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3013A (en) * | 1843-03-21 | James stewabt | ||
US7027A (en) * | 1850-01-15 | Circulak | ||
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
GB8329559D0 (en) | 1983-11-04 | 1983-12-07 | Erba Farmitalia | Furyl derivatives of 16-substituted prostaglandins preparations |
US5288754A (en) * | 1992-02-04 | 1994-02-22 | Allergan, Inc. | Polar C-1 esters of prostaglandins |
US5476872A (en) | 1993-10-18 | 1995-12-19 | Allergan, Inc. | 1,11-diesters of prostaglandin-F2α having a polar ester group at C-1 |
JP3162668B2 (ja) * | 1997-02-04 | 2001-05-08 | 小野薬品工業株式会社 | ω−シクロアルキル−プロスタグランジンE2誘導体 |
NO317155B1 (no) | 1997-02-04 | 2004-08-30 | Ono Pharmaceutical Co | <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater |
US6437146B1 (en) | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
US6376533B1 (en) | 2000-10-20 | 2002-04-23 | Allergan Sales, Inc. | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
US6410591B1 (en) | 2001-05-08 | 2002-06-25 | Allergan Sales, Inc. | 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
KR20050039733A (ko) | 2001-11-05 | 2005-04-29 | 알러간, 인코포레이티드 | EP₂-수용체 작용제로서의 ω-시클로알킬 17-헤테로아릴프로스타글란딘 E₂유사체 |
WO2006047466A2 (en) | 2004-10-21 | 2006-05-04 | Duke University | Ophthamological drugs |
US8162622B2 (en) | 2005-03-07 | 2012-04-24 | Carrier Corporation | Compressor sound suppression |
US20070254920A1 (en) | 2006-04-26 | 2007-11-01 | Aerie Pharmaceuticals, Inc. | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use |
US7547727B2 (en) | 2006-05-22 | 2009-06-16 | Allergan, Inc. | Therapeutic cyclopentane derivatives |
AU2006349143B2 (en) | 2006-10-02 | 2013-07-18 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates |
US8193373B2 (en) | 2006-12-11 | 2012-06-05 | Allergan, Inc. | Therapeutic compounds |
-
2009
- 2009-03-17 US US12/405,349 patent/US7960378B2/en active Active
- 2009-03-18 CA CA2718713A patent/CA2718713A1/en not_active Abandoned
- 2009-03-18 EP EP09721753A patent/EP2279169A2/en not_active Withdrawn
- 2009-03-18 AU AU2009225693A patent/AU2009225693B2/en not_active Ceased
- 2009-03-18 WO PCT/US2009/037477 patent/WO2009117467A2/en active Application Filing
- 2009-03-18 JP JP2011500916A patent/JP2011515409A/ja not_active Ceased
- 2009-03-19 BR BRPI0909764A patent/BRPI0909764A2/pt not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014517008A5 (ja) | ||
JP2013537203A5 (ja) | ||
JP2008513510A5 (ja) | ||
EP1857457A3 (en) | Benzimidazole derivative and its use as AII receptor antagonist | |
JP2010530897A5 (ja) | ||
JP2012500805A5 (ja) | ||
EP2620432A3 (en) | Diarylhydantoin compounds | |
JP2013525444A5 (ja) | ||
JP2012006970A5 (ja) | ||
JP2010525056A5 (ja) | ||
JP2015521167A5 (ja) | ||
JP2014508752A5 (ja) | ||
JP2011522827A5 (ja) | ||
JP2006524660A5 (ja) | ||
JP2009541216A5 (ja) | ||
JP2007538024A5 (ja) | ||
JP2013513613A5 (ja) | ||
JP2011006480A5 (ja) | ||
JP2013512277A5 (ja) | ||
JP2010510232A5 (ja) | ||
JP2009539828A5 (ja) | ||
JP2012528813A5 (ja) | ||
JP2011515409A5 (ja) | ||
JP2018537535A5 (ja) | ||
JP2015508092A5 (ja) |